1. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes – 2024. Diabetes Care 2024; 47(Suppl. 1): S20–S42, doi: 10.2337/dc24-S002.
2.
World Health Organization. Global report on diabetes. 2016. Available from URL: https://iris.who.int/handle/10665/204871.
3.
Saeedi P, Petersohn I, Salpea P, et al. IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 2019; 157: 107843, doi: 10.1016/j.diabres.2019.107843.
4.
Wong ND, Sattar N. Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention. Nat Rev Cardiol 2023; 20(10): 685–695, doi: 10.1038/s41569-023-00877-z.
5.
Simone G, de, Roman MJ, Alderman MH, et al. Is high pulse pressure a marker of preclinical cardiovascular disease? Hypertension 2005; 45(4): 575–579, doi: 10.1161/01.HYP.0000158268.95012.08.
6.
Schram MT, Chaturvedi N, Fuller JH, et al. EURODIAB Prospective Complications Study Group. Pulse pressure is associated with age and cardiovascular disease in type 1 diabetes: the Eurodiab Prospective Complications Study. J Hypertens 2003; 21(11): 2035–2044, doi: 10.1097/00004872-200311000-00012.
7.
Philips JC, Marchand M, Scheen AJ. Pulse pressure and cardiovascular autonomic neuropathy according to duration of type 1 diabetes. Diabetes Metab Res Rev 2009; 25(5): 442–451, doi: 10.1002/dmrr.969.
8.
Cockcroft JR, Wilkinson IB, Evans M, et al. Pulse pressure predicts cardiovascular risk in patients with type 2 diabetes mellitus. Am J Hypertens 2005; 18(11): 1463–1467, doi: 10.1016/j.amjhyper.2005.05.009.
9.
Roberto S, Milia R, Doneddu A, et al. Hemodynamic abnormalities during muscle metaboreflex activation in patients with type 2 diabetes mellitus. J Appl Physiol (1985); 2019; 126(2): 444–453, doi: 10.1152/japplphysiol.00794.2018.
10.
Rissanen AP, Tikkanen HO, Koponen AS, et al. Central and peripheral cardiovascular impairments limit VO(2peak) in type 1 diabetes. Med Sci Sports Exerc 2015; 47(2): 223–230, doi: 10.1249/MSS.0000000000000419.
11.
Sugita Y, Ito K, Yoshioka Y, et al. Association of complication of type 2 diabetes mellitus with hemodynamics and exercise capacity in patients with heart failure with preserved ejection fraction: a case-control study in individuals aged 65-80 years. Cardiovasc Diabetol 2023; 22(1): 97, doi: 10.1186/s12933-023-01835-2.
12.
Lav Madsen P, Sejersen C, Nyberg M, et al. The cardiovascular changes underlying a low cardiac output with exercise in patients with type 2 diabetes mellitus. Front Physiol 2024; 15: 1294369, doi: 10.3389/fphys.2024.1294369.
13.
Agnoletti D, Lieber A, Zhang Y, et al. Central hemodynamic modifications in diabetes mellitus. Atherosclerosis 2013; 230(2): 315–321, doi: 10.1016/j.atherosclerosis.2013.07.054. 1
14.
Urbina EM, Wadwa RP, Davis C, et al. Prevalence of increased arterial stiffness in children with type 1 diabetes mellitus differs by measurement site and sex: the SEARCH for Diabetes in Youth Study. J Pediatr 2010; 156(5): 731–737, doi: 10.1016/j.jpeds.2009.11.011.
15.
Podgórski M, Szatko K, Stańczyk M, et al. Two-Dimensional Speckle Tracking Versus Applanation Tonometry in Evaluation of Subclinical Atherosclerosis in Children with Type 1 Diabetes Mellitus. Med Sci Monit 2019; 25: 7289–7294, doi: 10.12659/MSM.916466.
16.
Dabelea D, Talton JW, D’Agostino R Jr, et al. Cardiovascular risk factors are associated with increased arterial stiffness in youth with type 1 diabetes: the SEARCH CVD study. Diabetes Care 2013; 36(12): 3938–3943, doi: 10.2337/dc13-0851.
17.
Giannopoulou EZ, Doundoulakis I, Antza C, et al. S. Subclinical arterial damage in children and adolescents with type 1 diabetes: A systematic review and meta-analysis. Pediatr Diabetes 2019; 20(6): 668–677, doi: 10.1111/pedi.12874.
18.
Carbone S, Dixon DL. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2019; 18(1): 64, doi: 10.1186/s12933-019-0869-2.
19.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023; 389(24): 2221–2232.
20.
Colhoun HM, Lingvay I, Brown PM, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med 2024; 30(7): 2058–2066, doi: 10.1038/s41591-024-03015-5.
21.
Siebert J, ed. Kardiografia impedancyjna przewodnik dla lekarzy. Gdańsk: Via Medica; 2006 (in Polish).
22.
Siebert K. Impedance techniques in medical practice. Folia Cardiologica 2020; 15(3): 236–242, doi: 10.5603/FC.a2020.0031.
23.
Krzesiński P, Siebert J, Jankowska EA, et al. Nurse-led ambulatory care supported by non-invasive haemodynamic assessment after acute heart failure decompensation. ESC Heart Fail 2021; 8(2): 1018–1026, doi: 10.1002/ehf2.13207/.
24.
Krzesiński P, Jankowska EA, Siebert J, et al. Effects of an outpatient intervention comprising nurse-led non-invasive assessments, telemedicine support and remote cardiologists decisions in patients with heart failure (AMULET study): a randomised controlled trial. Eur J Heart Fail 2022; 24(3): 565–577.
25.
Lewandowska A, Kręgielska-Narożna M, Bogdański P. Ocena sztywności naczyń jako element analizy ryzyka sercowo-naczyniowego. Forum Zaburzeń Metabolicznych 2017; 8(4): 161–170 (in Polish).
26.
Siebert J. Molisz A. Centralne ciśnienie tętnicze tonometria aplanacyjna. Forum Med Rodz 2010; 4(2): 141–148 (in Polish).
